Boston Scientific, a biomedical/biotechnology engineering firm, agreed to acquire Axonics, a medical technology company, for $3.4bn. "We are excited to add Axonics technologies to the Boston Scientific portfolio, a combination that we expect will further strengthen our ability to serve urologists who are treating patients living with these often-chronic conditions," Meghan Scanlon, Boston Scientific Senior Vice President and President, Urology. On March 22, 2024, Axonics stockholders approve the acquisition agreement with Boston Scientific.